Skip to Content

Cisplatin Dosage

Medically reviewed on September 24, 2018.

Applies to the following strengths: 50 mg; 10 mg; 1 mg/mL

Usual Adult Dose for Testicular Cancer

Metastatic testicular tumors: 20 mg/m2 IV over 6 to 8 hours daily for 5 days per cycle in combination with other approved chemotherapeutic agents

Comments:
-This drug should be administered by slow IV infusion. Do not give by rapid IV infusion.
-For directions for the administration of cyclophosphamide, refer to the cyclophosphamide package insert.
-Pretreatment hydration with 1 to 2 liters of fluid infused for 8 to 12 hours prior to a treatment cycle is recommended.

Use: In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received surgical and/or radiotherapeutic procedures

Usual Adult Dose for Ovarian Cancer

Metastatic Ovarian Tumors:
-As a single agent: 100 mg/m2 IV over 6 to 8 hours per cycle once every 4 weeks
-In combination with cyclophosphamide (give sequentially): Cisplatin 75 to 100 mg/m2 IV over 6 to 8 hours per cycle once every 4 weeks (Day 1); the dose of cyclophosphamide when used in combination with cisplatin is 600 mg/m2 IV once every 4 weeks (Day 1)

Comments:
-This drug should be administered by slow IV infusion. Do not give by rapid IV infusion.
-For directions for the administration of cyclophosphamide, refer to the cyclophosphamide package insert.
-Pretreatment hydration with 1 to 2 liters of fluid infused for 8 to 12 hours prior to a treatment cycle is recommended.

Use: In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received surgical and/or radiotherapeutic procedures; an established combination consists of this drug and cyclophosphamide; this drug, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received this drug

Usual Adult Dose for Bladder Cancer

50 to 70 mg/m2 IV over 6 to 8 hours per cycle once every 3 to 4 weeks depending on the extent of prior exposure to radiation therapy and/or prior chemotherapy; for heavily pretreated patients an initial dose of 50 mg/m2 per cycle repeated every 4 weeks is recommended

Comments:
-This drug should be administered by slow IV infusion. Do not give by rapid IV infusion.
-Pretreatment hydration with 1 to 2 liters of fluid infused for 8 to 12 hours prior to a treatment cycle is recommended.

Use: As a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy

Renal Dose Adjustments

Contraindicated in patients with preexisting renal impairment.

Liver Dose Adjustments

Data not available

Dose Adjustments

US BOXED WARNINGS:
-This drug should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when diagnostic and treatment facilities are readily available.
-Cumulative renal toxicity associated with this drug is severe.
-Other major dose-related toxicities are myelosuppression, nausea, and vomiting.
-This drug can cause ototoxicity (may be more pronounced in children) which is manifested by tinnitus, and/or loss of high frequency hearing and occasionally deafness.
-Anaphylactic-like reactions to this drug have been reported. Facial edema, bronchoconstriction, tachycardia, and hypotension may occur within minutes of administration. Epinephrine, corticosteroids, and antihistamines should be readily available.
-Exercise caution to prevent inadvertent overdose. Doses greater than 100 mg/m2/cycle once every 3 to 4 weeks are rarely used. Care should be taken to avoid inadvertent overdose due to confusion with carboplatin or prescribing practices that fail to differentiate daily doses from total dose per cycle.

CONTRAINDICATIONS:
-Hypersensitivity to the active component or any of the ingredients
-Hypersensitivity to other platinum-containing compounds
-Renal impairment
-In patients with hearing impairment
-Myelosuppression

This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Precautions

US BOXED WARNINGS:
-This drug should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when diagnostic and treatment facilities are readily available.
-Cumulative renal toxicity associated with this drug is severe.
-Other major dose-related toxicities are myelosuppression, nausea, and vomiting.
-This drug can cause ototoxicity (may be more pronounced in children) which is manifested by tinnitus, and/or loss of high frequency hearing and occasionally deafness.
-Anaphylactic-like reactions to this drug have been reported. Facial edema, bronchoconstriction, tachycardia, and hypotension may occur within minutes of administration. Epinephrine, corticosteroids, and antihistamines should be readily available.
-Exercise caution to prevent inadvertent overdose. Doses greater than 100 mg/m2/cycle once every 3 to 4 weeks are rarely used. Care should be taken to avoid inadvertent overdose due to confusion with carboplatin or prescribing practices that fail to differentiate daily doses from total dose per cycle.

CONTRAINDICATIONS:
-Hypersensitivity to the active component or any of the ingredients
-Hypersensitivity to other platinum-containing compounds
-Renal impairment
-In patients with hearing impairment
-Myelosuppression

This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-This drug should be administered by slow IV infusion. Do not give by rapid IV infusion.
-Pretreatment hydration with 1 to 2 liters of fluid infused for 8 to 12 hours prior to a treatment cycle is recommended.

Storage requirements:
-Procedures for proper handling and disposal of anticancer drugs should be utilized.

Reconstitution/preparation techniques:
-The manufacturer product information should be consulted.

General:
-Needles or IV sets containing aluminum parts that may contact this drug should not be used for preparation or administration. Aluminum reacts with this drug, causing precipitate formation and a loss of potency.

Monitoring:
-Peripheral blood counts should be monitored weekly.
-Liver function should be monitored periodically.
-Neurologic examination should be performed regularly.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide